Giulia Masuelli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Giulia Masuelli has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
- Arsenio Spinillo
Department of Obstetrics and Gynecology, Fondazione IRCCS Policlinico San Matteo, Università degli Studi di Pavia, 27100 Pavia, Italy
3 shared publications - Enrica Tamburrini
Institute of Clinical Infectious Diseases, Catholic University of Sacred Heart, Rome, Italy
3 shared publications - Irene Cetin
Complex Obstetrics Unit, Fondazione IRCCS Cà Granda, Ospedale Maggiore Policlinico, 20122 Milan, Italy
3 shared publications - Marco Floridia
National Center for Global Health, Istituto Superiore di Sanità, 00161 Rome, Italy
3 shared publications - Serena Dalzero
Department of Obstetrics and Gynaecology, DMSD San Paolo Hospital Medical School, University of Milan, Milan, Italy
3 shared publications - A. Meloni
Division of Gynaecology and Obstetrics S. Giovanni di Dio Hospital University of Cagliari Cagliari Italy
2 shared publications
Latest Publications
- 8 July 2019
- Published by Springer Nature in Infection
- Vol. 47 (6) , 981-990
Vaginal delivery in women with HIV in Italy: results of 5 years of implementation of the national SIGO-HIV protocol
To evaluate the maternal and neonatal safety of vaginal delivery in women with HIV following the implementation of a national protocol in Italy.
- 8 July 2019
- Published by Springer Nature in Infection
- Vol. 47 (6) , 981-990
Vaginal delivery in women with HIV in Italy: results of 5 years of implementation of the national SIGO-HIV protocol
To evaluate the maternal and neonatal safety of vaginal delivery in women with HIV following the implementation of a national protocol in Italy.
- Open Access
- 17 July 2017
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 145 (11) , 2360-2365
Pregnant with HIV before age 25: data from a large national study in Italy, 2001–2016
SUMMARY: Young pregnant women with HIV may be at significant risk of unplanned pregnancy, lower treatment coverage, and other adverse pregnancy outcomes. In a large cohort of pregnant women with HIV in Italy, among 2979 pregnancies followed in 2001–2016, 9·0% were in women P< 0·001). Younger women had a lower rate of planned pregnancy (23·2%vs.37·7%, odds ratio (OR) 0·50, 95% confidence interval (CI) 0·36–0·69), were more frequently diagnosed with HIV in pregnancy (46·5%vs.20·9%, OR 3·29, 95% CI 2·54–4·25), and, if already diagnosed with HIV before pregnancy, were less frequently on antiretroviral treatment at conception (vs.99·3%), with no differences in rate of HIV viral suppression at third trimester and adverse pregnancy outcomes. The data show that young women represent a growing proportion of pregnant women with HIV, and are significantly more likely to have unplanned pregnancy, undiagnosed HIV infection, and lower treatment coverage at conception. During pregnancy, antiretroviral treatment, HIV suppression, and pregnancy outcomes are similar compared with older women. Earlier intervention strategies may provide additional benefits in the quality of care for women with HIV.
- 17 July 2017
- Published by Cambridge University Press (CUP) in Epidemiology and Infection
- Vol. 145 (11) , 2360-2365
Open AccessPregnant with HIV before age 25: data from a large national study in Italy, 2001–2016
SUMMARY: Young pregnant women with HIV may be at significant risk of unplanned pregnancy, lower treatment coverage, and other adverse pregnancy outcomes. In a large cohort of pregnant women with HIV in Italy, among 2979 pregnancies followed in 2001–2016, 9·0% were in women P< 0·001). Younger women had a lower rate of planned pregnancy (23·2%vs.37·7%, odds ratio (OR) 0·50, 95% confidence interval (CI) 0·36–0·69), were more frequently diagnosed with HIV in pregnancy (46·5%vs.20·9%, OR 3·29, 95% CI 2·54–4·25), and, if already diagnosed with HIV before pregnancy, were less frequently on antiretroviral treatment at conception (vs.99·3%), with no differences in rate of HIV viral suppression at third trimester and adverse pregnancy outcomes. The data show that young women represent a growing proportion of pregnant women with HIV, and are significantly more likely to have unplanned pregnancy, undiagnosed HIV infection, and lower treatment coverage at conception. During pregnancy, antiretroviral treatment, HIV suppression, and pregnancy outcomes are similar compared with older women. Earlier intervention strategies may provide additional benefits in the quality of care for women with HIV.
- 1 September 2016
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 22 (9) , 818-820
Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV
- 1 September 2016
- Published by Elsevier in Clinical Microbiology and Infection
- Vol. 22 (9) , 818-820
Pregnancy outcomes and cytomegalovirus DNAaemia in HIV-infected pregnant women with CMV
- Open Access
- 20 June 2016
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 124 (8) , 1218-1223
Amniocentesis and chorionic villus sampling in HIV‐infected pregnant women: a multicentre case series
Objectives: To assess in pregnant women with HIV the rates of amniocentesis and chorionic villus sampling (CVS), and the outcomes associated with such procedures.Design: Observational study. Data from the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy were used.Setting: University and hospital clinics.Population: Pregnant women with HIV.Methods: Temporal trends were analysed by analysis of variance and by the Chi‐square test for trend. Quantitative variables were compared by Student's t‐test and categorical data by the Chi‐square test, with odds ratios and 95% confidence intervals calculated.Main outcome measures: Rate of invasive testing, intrauterine death, HIV transmission.Results: Between 2001 and 2015, among 2065 pregnancies in women with HIV, 113 (5.5%) had invasive tests performed. The procedures were conducted under antiretroviral treatment in 99 cases (87.6%), with a significant increase over time in the proportion of tests performed under highly active antiretroviral therapy (HAART) (100% in 2011–2015). Three intrauterine deaths were observed (2.6%), and 14 pregnancies were terminated because of fetal anomalies. Among 96 live newborns, eight had no information available on HIV status. Among the remaining 88 cases with either amniocentesis (n = 75), CVS (n = 12), or both (n = 1), two HIV transmissions occurred (2.3%). No HIV transmission occurred among the women who were on HAART at the time of invasive testing, and none after 2005.Conclusions: The findings reinforce the assumption that invasive prenatal testing does not increase the risk of HIV vertical transmission among pregnant women under suppressive antiretroviral treatment.Tweetable No HIV transmission occurred among women who underwent amniocentesis or CVS under effective anti‐HIV regimens.
- 20 June 2016
- Published by Wiley in BJOG: An International Journal of Obstetrics & Gynaecology
- Vol. 124 (8) , 1218-1223
Open AccessAmniocentesis and chorionic villus sampling in HIV‐infected pregnant women: a multicentre case series
Objectives: To assess in pregnant women with HIV the rates of amniocentesis and chorionic villus sampling (CVS), and the outcomes associated with such procedures.Design: Observational study. Data from the Italian National Program on Surveillance on Antiretroviral Treatment in Pregnancy were used.Setting: University and hospital clinics.Population: Pregnant women with HIV.Methods: Temporal trends were analysed by analysis of variance and by the Chi‐square test for trend. Quantitative variables were compared by Student's t‐test and categorical data by the Chi‐square test, with odds ratios and 95% confidence intervals calculated.Main outcome measures: Rate of invasive testing, intrauterine death, HIV transmission.Results: Between 2001 and 2015, among 2065 pregnancies in women with HIV, 113 (5.5%) had invasive tests performed. The procedures were conducted under antiretroviral treatment in 99 cases (87.6%), with a significant increase over time in the proportion of tests performed under highly active antiretroviral therapy (HAART) (100% in 2011–2015). Three intrauterine deaths were observed (2.6%), and 14 pregnancies were terminated because of fetal anomalies. Among 96 live newborns, eight had no information available on HIV status. Among the remaining 88 cases with either amniocentesis (n = 75), CVS (n = 12), or both (n = 1), two HIV transmissions occurred (2.3%). No HIV transmission occurred among the women who were on HAART at the time of invasive testing, and none after 2005.Conclusions: The findings reinforce the assumption that invasive prenatal testing does not increase the risk of HIV vertical transmission among pregnant women under suppressive antiretroviral treatment.Tweetable No HIV transmission occurred among women who underwent amniocentesis or CVS under effective anti‐HIV regimens.